Fol. Biol. 2012, 58, 231-237
https://doi.org/10.14712/fb2012058060231
Paraoxonase-1 (PON1) Status in Pancreatic Cancer: Relation to Clinical Parameters
References
1. 1996) Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin. Biochem. 29, 139-144.
< , M., Ruutu, M., Mäntylä, E. (https://doi.org/10.1016/0009-9120(95)02043-8>
2. 2003) Serum paraoxonase levels in pancreatic cancer. HepatoGastroenterology 50, Suppl II, ccxxv-ccxxvii.
, M. N., Polat, M. F., Yilmaz, I., Akcay, G. (
3. 1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet. Med. 15, 539-553.
< , K. G., Zimmet, P. Z. (https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S>
4. 2009) Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur. J. Gynaecol. Oncol. 30, 679-682.
, D. T., Camuzcuoglu, H., Toy, H., Kurt, S., Celik, H., Erel, O. (
5. 2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276.
< , T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmidt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., Hazen, S. L. (https://doi.org/10.1001/jama.299.11.1265>
6. 2002) Paraoxonase-1 L55M polymorphism is associated with abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J. Clin. Endocrin. Metab. 87, 1268-1273.
< , S., Leviev, I., Nicaud, V., Gustini, P., Grison, E., Pizzolo, F., Friso, S., Trabetti, E., Pignatti, P.F., Corrocher, R., Olivieri, O., Girelli, D. (https://doi.org/10.1210/jcem.87.3.8335>
7. 2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 107, 435-447.
< , S. P., James, R. W. (https://doi.org/10.1042/CS20040187>
8. 2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275, 33435-33442.
< , D. I., Stetson, P. L., Watson, C. E., Billecke, S. S., La Du, B. N. (https://doi.org/10.1074/jbc.M004543200>
9. 2007) Paraoxonase, total antioxidant activity and peroxide levels in marasmic children: relationships with leptin. Clin. Biochem. 40, 634-639.
< , A., Gürkan, F., Celik, F., Boşnak, M., Yel, S., Balik, H., Erel, O. (https://doi.org/10.1016/j.clinbiochem.2007.03.001>
10. 2012) Different effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol. Biol. Rep. 39, 6801-6809.
< , D. H., Fan, C. H., Ji, Q., Qi, B. X., Li, J, Wang, L. (https://doi.org/10.1007/s11033-012-1505-3>
11. 2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer. 46, 745-781.
< , J., Parkin, D. M., Steliarova-Foucher, E. (https://doi.org/10.1016/j.ejca.2009.12.014>
12. 2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res. 57, 717-726.
< , M., Škrha, J., Zídková, K., Lacinová, Z., Hilgertová, J. (https://doi.org/10.33549/physiolres.931285>
13. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P., O’Sullivan, B., Sobin, L. H., Yarbro, J. W. (eds.) (1997) AJCC. Cancer Staging Manual. 5th ed. Philadelphia-New York, Lippincott-Raven.
14. 2009) Paraoxonase: a multifaceted biomolecule. Clin. Chim. Acta 410, 1-12.
< , B., Tayal, D., Gupta, N., Mallika, V. (https://doi.org/10.1016/j.cca.2009.09.025>
15. 2007) Risk factors for pancreatic cancer: case-control study. Am. J. Gastroenterol. 102, 2696-2707.
< , M. M., Bondy, M. L., Wolff, R. A., Abbruzzese, J. L., Vauthey, J. N., Postere, P. W., Evans, D. B., Khan, R., Chou, T. H., Lenzi, R., Jiao, L., Li, D. (https://doi.org/10.1111/j.1572-0241.2007.01510.x>
16. 2000) Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320.
< , C. C., Thorpe, S. R., Fu, M. X., Harper, C. M., Yoo, J., Kim, S. M., Wong, H., Peters, A. L. (https://doi.org/10.1007/s001250050049>
17. 2011) Association of L55M a Q192 polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol. Cell. Biochem. 351, 117-123.
< , Y. M., Gharib, A. F., Etewa, R. L., ElSawy, W. H. (https://doi.org/10.1007/s11010-011-0718-4>
18. Institute of Health Information and Statistics of the Czech Republic (IHIS) and Council of the National Oncological Registry of the Czech Republic (NOR) (2011) Cancer Incidence 2008. ÚZIS and NOR ČR. Prague.
19. 2006) A long and winding road: defining the biological role and clinical importance of paraoxonase. Clin. Chem. Lab. Med. 44, 1052-1059.
< , R. W. (https://doi.org/10.1515/CCLM.2006.207>
20. 2010) Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J. Craniofac. Surg. 21, 1745-1749.
< , E., Uzun, H., Papila, I., Balci, H., Ozdilek, A., Genc, H., Yanardag, H., Papila, C. (https://doi.org/10.1097/SCS.0b013e3181f4040a>
21. 2009) Antioxidative enzymes and increased oxidative stress in depressive women. Clin. Biochem. 42, 1368-1374.
< , J., Vávrová, L., Zeman, M., Jirák, R., Macášek, J., Staňková, B., Tvrzická, E., Žák, A. (https://doi.org/10.1016/j.clinbiochem.2009.06.006>
22. 2011) Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 58, 58-64.
< , T., Zeman, M., Vecka, M., Macášek, J., Jáchymová, M., Zima, T., Žák, A. (https://doi.org/10.4149/neo_2011_01_58>
23. 2005) Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of paraoxonase-1 (PON-1) gene on lung cancer. J. Prev. Med. Publ. Health 38, 345-350.
, C. H., Lee, K. Y., Choe, K. H., Hong, Y. C., Kim, Y. D., Kang, J. W., Kim, H. (
24. 2010) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Chachexia Sarcopenia Muscle 1, 9-21.
< , K., Schuler, G., Adams, V. (https://doi.org/10.1007/s13539-010-0007-1>
25. 2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20, 516-521.
< , I., James, R. W. (https://doi.org/10.1161/01.ATV.20.2.516>
26. 1997) Effect of molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122, 265-268.
< , B., Mackness, M. I., Arron, S., Turkie, W., Durrington, P. N. (https://doi.org/10.1038/sj.bjp.0701390>
27. 2003) Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24-38.
< , A. C., Sanders, R. A., Watkins, J. B. (https://doi.org/10.1002/jbt.10058>
28. 2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226.
< , D. C. (https://doi.org/10.1097/MCO.0b013e32832a7902>
29. 1988) A simple salting out extraction DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
< , S. A., Dykes, D. D., Polesky, H. F. (https://doi.org/10.1093/nar/16.3.1215>
30. 2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134, 981-987.
< , R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., Chari, S. T. (https://doi.org/10.1053/j.gastro.2008.01.039>
31. 2011) The three-gene paraoxonase family: physiologic roles, action and regulation. Atherosclerosis 214, 20-36.
< , L. P., Amre, D., Denis, M. C., Lavore, J. C., Delvin, E., Seidman, E., Levy, E. (https://doi.org/10.1016/j.atherosclerosis.2010.08.076>
32. 2011) Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase 1) enzymes and lipid parameters in different cancer patients. Clin. Lab. 57, 741-747.
, Z. Q., Pervaiz, S., Shaheen, S., Dar, N., Athar, M. A. (
33. 2011) L-carnitine and cancer cachexia: clinical and experimental aspects. J. Cachexia Sarcopenia Muscle 2, 3744.
< , R., Lavino, A., Rossi Fanelli, F., Seelaender, M. (https://doi.org/10.1007/s13539-011-0017-7>
34. 2009) Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 20, 265-274.
< , H., Younis, N. N., Charlton-Menys, V., Durrington, P. (https://doi.org/10.1097/MOL.0b013e32832ec141>
35. 2011) Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic. Biol. Med. 50, 148-156.
< , H., Aviram, M., Khatib, S., Musa, R., Mannheim, D., Karmeli, R., Vaya, J. (https://doi.org/10.1016/j.freeradbiomed.2010.10.708>
36. 2006) Free radicals, metals, and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160, 1-40.
< , M., Rhodes, C. J., Moncol, J., Izakovic, M., Mazur, M. (https://doi.org/10.1016/j.cbi.2005.12.009>
37. 2008) Paraoxonase 1 phenotype distribution and activity differ in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet. Med. 25, 186-193.
< , S. W., Jansen, E. H., Kruijshoop, M., Beekhof, P. K., Blaak, E., van der Kallen, C. J., van Greevenbroek, M. M., Feskens, E. J. (https://doi.org/10.1111/j.1464-5491.2007.02328.x>